Alex: vometinib mesylate tablets are newly included in the national medical insurance catalogue
Financial Associated Press, Dec. 3 (Reuters) - Alex announced that the company's product vometinib mesylate passed the medical insurance negotiation and was included in the national catalogue of drugs for basic medical insurance, industrial injury insurance and maternity insurance (2021) for the first time. Vometinib mesylate tablet is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). It is a class 1 new drug independently developed by the company. It is a small molecule targeted drug for the treatment of advanced non-small cell lung cancer.
This text is a result of machine translation.
Related companies：
In-depth
Jan 30, 2024 07:59 PM
Dec 11, 2023 08:49 PM
Jan 05, 2023 07:33 PM
Nov 16, 2022 05:19 PM
Consumer Staples
POP MART Announces the Global Organizational Structure Upgrade
Apr 15, 2025 03:45 PM
See more
Read next
Insight
In-depth
Automotive · Analysis
Chinese Automakers Break into a €10 Billion Market in Europe
Apr 11, 2025 09:57 PM
Insight
In-depth
Automotive · Analysis
Tariff Escalation Through the Lens of Geopolitical Economy
Apr 11, 2025 12:32 PM
Insight
In-depth
Consumer Staples · Analysis
China’s “Dark Cuisine” and Southeast Asia’s Wealth Code
Apr 07, 2025 03:46 PM
Insight
In-depth
